Individual
DC projects
Research project
Targeting Metabolic Pathways in Leukemic Stem Cells for AML Treatment
Rationale and Objectives
Previous work has shown that combining the SLC7A5 inhibitor JPH203 with Ven and Aza effectively targets oxidative respiration, promoting the eradication of leukemic stem cells (LSCs) in vitro, even in resistant AML patient samples.
Building on these findings, this project will evaluate the in vivo efficacy of the triple therapy using pre-clinical mouse models through the following specific objectives:
- Investigating the impact of triple Ven + Aza + JPH203 treatment on long-term disease onset and LSC viability in pre-clinical and mouse models of AML, Clonal Hematopoiesis of Indeterminate Potential (CHIP), and childhood leukemia.
- Evaluating the molecular and functional features of the LSC compartment in treated mice through flow cytometry, RNA-seq, and metabolomics analysis.
- Exploring additional metabolic susceptibility targets affecting LSC populations and overall disease progression in vivo.
Estimated gross salary
54,000CHF/year
This project may be adapted to the evolving needs of the host laboratory while remaining within hemato-oncology research. The DC will undertake one or more secondments with a total duration of at least three months and up to one year. These secondments may take place within or outside the DN, preferably in international and intersectoral settings.